SelectION is a clinical-stage biopharmaceutical company founded with the mission to develop novel peptide therapies for autoimmune diseases and select cancer indications. The company focuses on targeting autoreactive, chronically activated T cells through its innovative technology platform, which enables the creation of potent and highly selective peptide blockers for ion channels involved in various diseases. This platform allows SelectION to optimize target selectivity, offering the potential to develop drugs with significantly improved efficacy and safety profiles.

Notable figures affiliated with SelectION include its experienced Management Board and Scientific Advisory Board, comprising experts in biopharmaceuticals and drug development. Key investors support the company’s ambitious research and development efforts. SelectION's achievements include advancing its lead candidate, si-544, into clinical trials for conditions like psoriasis vulgaris and psoriatic arthritis. The company’s work has the potential to significantly impact the treatment landscape for autoimmune diseases and certain cancers, offering new hope for patients with these challenging conditions.